Junyelt (Copper Gluconate, Manganese Gluconate, Potassium Iodide, Sodium Selenite, Zinc Gluconate)

The gluconate and salt forms dissociate after infusion, releasing free copper, manganese, iodine, selenium, and zinc ions. These trace elements act as essential cofactors for enzymes involved in oxidative‑stress defense, thyroid hormone synthesis, DNA repair, and immune cell activity, thereby helping restore normal metabolic and immune processes.

The dose of Junyelt is individualized by the prescribing clinician based on the patient’s laboratory values, clinical condition, and nutritional needs. Healthcare professionals determine the appropriate volume and concentration to achieve target trace‑element levels while avoiding excess.

Safety data for Junyelt in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it must be prescribed and monitored by a qualified healthcare provider.

To place an order, submit an enquiry on the Junyelt product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Junyelt combines five essential trace elements in a single intravenous formulation, which can simplify dosing compared with using separate single‑element preparations. This integrated approach may reduce infusion time and the risk of incompatibility, while still delivering the same therapeutic concentrations required for deficiency correction.

Junyelt must be stored at 2‑8 °C, protected from light, and kept in its original packaging. It should not be frozen or shaken vigorously. If the product reaches room temperature, it should be used promptly and any unused portion discarded according to local regulations.

Junyelt is administered intravenously as a sterile solution for injection. The infusion rate and duration are determined by the prescribing clinician, typically delivered through a peripheral or central line under aseptic conditions, with monitoring for any immediate adverse reactions.

The most serious risks include anaphylactic reactions, severe electrolyte imbalances (especially excess copper or zinc), and hepatic dysfunction. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after the infusion.

Junyelt should be avoided in individuals with known hypersensitivity to any of its components, in patients with untreated Wilson’s disease or manganese overload, and in those receiving concurrent high‑dose oral mineral supplements that could cause toxicity without medical supervision.